In summary, the study provides reassuring evidence that GLP-1 receptor agonists and DPP-4 inhibitors do not increase the risk of acute pancreatitis in patients with type 2 diabetes. Although a modest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback